Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1219

1.

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.

2.

Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.

Nitta Y, Shimizu S, Shishido-Hara Y, Suzuki K, Shiokawa Y, Nagane M.

Cancer Med. 2016 Mar;5(3):486-99. doi: 10.1002/cam4.614. Epub 2016 Jan 18.

3.

On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.

Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, Cairncross JG, Weiss S.

Neuro Oncol. 2013 Feb;15(2):198-207. doi: 10.1093/neuonc/nos302. Epub 2012 Dec 21.

4.

p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.

Miao W, Liu X, Wang H, Fan Y, Lian S, Yang X, Wang X, Guo G, Li Q, Wang S.

Mol Med Rep. 2015 Jun;11(6):4165-73. doi: 10.3892/mmr.2015.3255. Epub 2015 Jan 26.

5.

NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.

Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.

Cancer Lett. 2015 Oct 10;367(1):58-68. doi: 10.1016/j.canlet.2015.07.007. Epub 2015 Jul 15.

PMID:
26188279
6.

Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.

Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H, Tanaka S.

Cancer Lett. 2013 Apr 30;331(1):68-75. doi: 10.1016/j.canlet.2012.12.005. Epub 2012 Dec 12.

PMID:
23246370
7.

Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.

Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun SH, Kim HH, Kim IA.

BMC Cancer. 2014 Jan 13;14:17. doi: 10.1186/1471-2407-14-17.

8.

Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.

Lan F, Yang Y, Han J, Wu Q, Yu H, Yue X.

Int J Oncol. 2016 Feb;48(2):559-68. doi: 10.3892/ijo.2015.3271. Epub 2015 Nov 27.

PMID:
26648123
9.

The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.

Atif F, Patel NR, Yousuf S, Stein DG.

PLoS One. 2015 Jun 25;10(6):e0131441. doi: 10.1371/journal.pone.0131441. eCollection 2015.

10.

The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.

Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2013 Oct 15;19(20):5722-32. doi: 10.1158/1078-0432.CCR-13-0527. Epub 2013 Sep 12.

11.

Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.

Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Sep 15;20(18):4894-903. doi: 10.1158/1078-0432.CCR-13-1856. Epub 2014 Jul 30.

12.

The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.

Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K, Tofilon PJ.

Neuro Oncol. 2014 Jan;16(1):29-37. doi: 10.1093/neuonc/not139. Epub 2013 Dec 4.

13.

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, Ballman KV, Kitange GJ, Sarkaria JN.

Neuro Oncol. 2013 Jun;15(6):735-46. doi: 10.1093/neuonc/not010. Epub 2013 Mar 10.

14.

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.

Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, Ballman KV, Buckner JC, James CD, Sarkaria JN.

J Neurooncol. 2009 Mar;92(1):23-31. doi: 10.1007/s11060-008-9737-8. Epub 2008 Nov 15.

15.

Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.

Joshi AD, Loilome W, Siu IM, Tyler B, Gallia GL, Riggins GJ.

PLoS One. 2012;7(10):e44372. doi: 10.1371/journal.pone.0044372. Epub 2012 Oct 2.

16.

Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.

Boccard SG, Marand SV, Geraci S, Pycroft L, Berger FR, Pelletier LA.

Oncotarget. 2015 Oct 6;6(30):29456-68. doi: 10.18632/oncotarget.4909.

17.

Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.

Grogan PT, Sarkaria JN, Timmermann BN, Cohen MS.

Invest New Drugs. 2014 Aug;32(4):604-17. doi: 10.1007/s10637-014-0084-7. Epub 2014 Apr 10.

18.

Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.

Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RL.

J Natl Cancer Inst. 2012 Jan 4;104(1):42-55. doi: 10.1093/jnci/djr509. Epub 2011 Dec 15.

19.

Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.

Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, Rey JA, Sunguroğlu A, Castresana JS, Ugur HC.

Tumour Biol. 2013 Jun;34(3):1935-47. doi: 10.1007/s13277-013-0738-7. Epub 2013 Mar 22.

PMID:
23519841
20.

Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.

Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L.

Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/cddis.2014.188.

Supplemental Content

Support Center